LRRC3B and breast cancer: LRRC3B rs1907168 was related to the reduced risk of BC among young participants (age < 51 years) under the allele (OR = 0.69, 95% CI: 0.48–0.99, p = 0.043), heterozygote (OR = 0.53, 95% CI: 0.35–0.80, p = 0.002), dominant (OR = 0.58, 95% CI: 0.39–0.86, p = 0.008) and log-additive (OR = 0.68, 95% CI: 0.47–0.98, p = 0.038) models.